<DOC>
	<DOCNO>NCT00250861</DOCNO>
	<brief_summary>The purpose research study find treatment rituximab combination aldesleukin ( compare rituximab alone ) decrease risk cancer returning , well determine effect ( good bad ) drug combination NHL . Rituximab aldesleukin approve combination Food Drug Administration ( FDA ) treatment non-Hodgkins lymphoma ; however , Rituximab approve use treat NHL .</brief_summary>
	<brief_title>Trial Outpatient Immunotherapy With Rituximab Aldesleukin ( IL-2 ) vs. Rituximab Alone Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>INCLUSION CRITERIA : A patient eligible inclusion study s/he meet follow criterion : Has previously undergone BEAC BEAM autologus SCT PBSC rescue stage aggressive Bcell NHL , include transform indolent NHL mantle cell lymphoma accord REAL classification Bcell lymphomas permit . ECOG performance status 01 . Previously histological document CD20 +NHL . Is great 18 year age . Is 30100 day autologous peripheral blood stem cell transplant . Must meet laboratory value ( see protocol value ) : Absolute neutrophil , hemoglobin platelet . Has negative serum pregnancy test within 7 day prior trial registration ( female patient childbearing potential ) . If fertile , patient ( male female ) agree use physicianapproved method birth control avoid pregnancy duration study period 3 month thereafter . Has sign Patient Informed Consent Form . Has sign Patient Authorization Form ( HIPAA ) . EXCLUSION CRITERIA : Patients take treatment follow occur : ECOG PS &gt; 2 . A history hypersensitivity study drug , component thereof , anaphylactic history murine protein . Manifested cardiac complication transplant , include arrthymias , congestive heart failure , angina , myocardial infarct , decrease LVEF &lt; 45 % prior transplant On systemic corticosteroid . Diffusion capacity &lt; 60 % ( correct ) decrease 30 % follow transplant Documented disease progression ( See Section 10.1.6 definition ) . Active infection , and/or know seropositive hepatitis B , hepatitis C , HIV Pericardial effusion , pleural effusion , ascites . A history aggressive NHL , Burkitt 's atypical Burkitt 's lymphoma Receiving concurrent immunotherapy rituximab therapy . Previously receive solid organ transplant . History CNS involvement . A serious uncontrolled intercurrent medical psychiatric illness , include serious infection A history malignancy within last 5 year ( except cure basal cell carcinoma skin carcinoma situ uterine cervix ) , could affect diagnosis assessment study drug . A pregnant nursing woman . Unable comply requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>